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Abstract
OBJECTIVES—Toll-like receptors (TLR) are innate immune sensors that are integral to
resisting chronic and opportunistic infections. Mounting evidence implicates TLR polymorphisms
in susceptibilities to various infectious diseases, including HIV-1. We investigated the impact of
TLR single-nucleotide polymorphisms (SNPs) on clinical outcome in a sero-incident cohort of
HIV-1-infected volunteers.
DESIGN—We analyzed TLR SNPs in 201 antiretroviral treatment-naïve HIV-1 infected subjects
from a longitudinal sero-incident cohort with regular follow-up intervals (median follow-up 4.2
years, interquartile range 4.4). Subjects were stratified into two groups according to either disease
progression, defined as peripheral blood CD4+ T-cell decline over time, or peak and setpoint viral
load.
METHODS—Haplotype-tagging SNPs from TLR2, TLR3, TLR4, and TLR9 were detected by
mass-array genotyping, and CD4+ T-cell counts and viral load measurements were determined
prior to antiretroviral therapy initiation. The association of TLR haplotypes with viral load and
rapid progression was assessed by multivariate regression models using age and sex as covariates.
RESULTS—Two TLR4 SNPs in strong linkage disequilibrium (1063A/G [D299G] and 1363C/T
[T399I]) were more frequent among subjects with high peak viral load compared to low/moderate
peak viral load (OR=6.65, 95% CI 2.19–20.46, P<0.001; adjusted P=0.002 for 1063A/G). In
addition, a TLR9 SNP previously associated with slow progression was found less frequently
among subjects with high viral setpoint compared to low/moderate setpoint (OR=0.29, 95% CI
0.13–0.65, P=0.003, adjusted P=0.04).
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CONCLUSION—This study suggests a potentially new role for TLR4 polymorphisms in HIV-1
peak viral load and confirms a role for TLR9 polymorphisms in disease progression.
Keywords
HIV-1; Innate Immunity; HIV genetics; HIV immunology; Single Nucleotide Polymorphism;
Toll-Like Receptor 9; Toll-Like Receptor 4
INTRODUCTION
Persons with HIV-1 infection exhibit a high degree of variability in their rate of progression
to immunodeficiency and associated complications. In the absence of anti-retroviral
treatment, some infected persons progress to AIDS within 1–5 years, while others may
remain asymptomatic for over twenty years [1–4]. A large accumulation of data has
demonstrated a significant contribution of human leukocyte antigen (HLA) haplotypes to
this variability of disease progression rates. For example, certain HLA alleles lend
remarkable protection from viral escape mutations [5,6], while others are associated with
more prolific viral escape mutation [7,8]. Heightened expression levels of β-chemokines and
lower expression of the inhibitory receptors of CTLA-4 and PD-1 are examples of other
mechanisms that can slow disease progression [9–12]. Although some of these mechanisms
of resistance to disease progression have been associated with genetic polymorphisms, such
as possessing certain HLA-B alleles [13–15], HLA-heterozygosity [7,16], β-chemokines,
and their receptors CCR5 and CXCR4 [17,18], it is likely that other genes are also
associated with these differences.
Toll-like receptors (TLRs) are transmembrane proteins expressed on most immune cells that
detect specific molecular patterns on bacteria, viruses, fungi, and parasites, and stimulate the
production of innate immune effectors, such as inflammatory and chemotactic cytokines
[19]. Support for the central role of TLR activation in both the innate and adaptive immune
responses comes partially from TLR polymorphisms that have been shown to influence
susceptibility to a number of infectious human pathogens [20–27]. For example, HIV-1
virions can activate TLR7/8 directly with the single-stranded RNA genome, and the HIV-1
envelope protein, gp120, has been shown to inhibit TLR9-triggered plasmacytoid dendritic
cell (pDC) activation and interferon alpha (IFN-α) production [28–30]. TLRs also have
indirect effects on HIV-1 pathogenesis, such as when B cells from viremic HIV-infected
individuals lose their ability to proliferate in response to TLR9 stimulation [31]. Finally, the
lower levels of IFN-α in response to TLR7 and TLR9 agonists in sooty mangabeys are
characteristic of the naturally-occurring non-pathogenic SIV infection in these primates [32].
Recently two studies have highlighted a role for TLR9 polymorphisms in the clinical
manifestations of HIV-1 infection [24,33]. Although these findings have begun to shed light
on the role of innate immunity in HIV-1 infection, both studies were limited by several
biases and differing definitions of disease progression. The Swiss HIV Cohort Study is a
sero-prevalent cohort established before highly-active anti-retroviral therapy (HAART) was
widely available; therefore, rapid progressors may not have been included due to higher
mortality rates, and the analyses may have been influenced by onset confounding or
differential-length biases. In contrast, Soriano-Sarabia and colleagues analyzed a therapeutic
cohort comprised of patients who entered at treatment initiation. This clinical timepoint can
be influenced by contemporaneous clinical practices and drug availability can change over
time [33], and thus could bias towards less enrollment of rapid progressors as treatment
initiation criteria became more stringent. Furthermore, although one TLR gene was
examined by tagging SNPs in the Swiss HIV Cohort Study, both studies primarily examined
only those SNPs that had previously reported associations with other pathologies. Haplotype
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analyses using tagging SNPs take into account the shared evolutionary history of many
correlated SNPs (i.e., linkage-disequilibrium), and allow for an optimized approach to
haplotype association analyses [34,35], and neither of these two HIV-1 disease progression
studies utilized an objective sampling of TLR haplotype tagging SNPs. In an attempt to
overcome these limitations, we examined the role of haplotype tagging SNPs in several TLR
genes in disease progression using a sero-incident cohort of subjects with an extensive
longitudinal clinical and virological database.
METHODS
Study Populations
The Seattle Primary Infection Cohort (PIC) is a longitudinal sero-incident cohort of HIV-
infected individuals enrolling volunteers during the acute stages of disease. Enrollment
criteria have been previously reported in detail elsewhere [36]. Briefly, individuals were
enrolled within 90 days of HIV-1 infection, confirmed by viral RNA and antibody tests, and
followed-up for sample and clinical data collection bi-weekly for one month, monthly for a
quarter, and quarterly thereafter. The PIC is over 90% Caucasian; therefore, we restricted
the analysis to white enrollees only to reduce the risk of population stratification. All
individuals gave written informed consent for these studies and the study was approved by
the Institutional Review Boards of the University of Washington and the Fred Hutchinson
Cancer Research Center, as well as the Western Institutional Review Board.
HIV-1 plasma viral load in volunteers was determined by bDNA assay (Bayer, Terrytown,
NY) and/or quantitative reverse-transcription PCR (Roche, Pleasanton, CA) [37–39]. The
PIC includes subjects who were enrolled during the early stages of HIV-1 infection,
allowing assessment of peak viral loads before a set-point viral load is established. The peak
viral load was defined by the maximum amount of HIV-1 plasma RNA observed during the
first 100 days following the determined date of HIV-1 infection and before ART/HAART
has been started. The setpoint was defined as the mean viral load during days 100–730 after
infection and before initiation of ART/HAART [40]. CD4+ T cells in peripheral blood were
measured at each follow-up visit by routine flow cytometry methods (BD Biosciences, San
Jose, CA) [39], and disease progression was defined as the rate of CD4+ T-cell count decline
over time in the absence of ART [41–43]. Quantitation of CD4 slope measurement was
determined using a linear regression of time versus the square root of the CD4+ T-cell count,
as described previously [24,42]. Values of CD4 slopes and viral loads were categorized into
thirds to define test groups of rapid progressors or high viral load subjects, respectively.
Rapid progressors were defined as those participants with CD4 slopes below the lower
tertile (steepest slopes), and all remaining subjects with CD4 slopes above this value were
defined as slow/moderate progressors. High and low/moderate viral load test subjects were
similarly defined using the higher tertile of log10-transformed viral load values. Gender-
specific tertiles were defined separately to account for the high proportion of males present
in the cohort. To check for potential biases in our cohort definitions we reversed the
designation of cases from rapid progressors/high viral loads to slow progressors/low viral
loads and obtained the converse results of our original analyses.
Genotyping
Fourteen haplotype tagging SNPs were retrieved for TLR2, TLR3, TLR4 and TLR9 from the
Innate Immunity Program in Genomic Applications (http://innateimmunity.net), and cross-
referenced for function and location in dbSNP public database (http://ncbi.nlm.nih.gov).
Five additional SNPs that had previously been associated with a human disease and/or
predicted to induce an amino-acid change in the protein were also genotyped [20]. DNA was
extracted from cryopreserved peripheral blood mononuclear cells or EBV-transformed B
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cell lines with QIAamp DNA Blood Mini kits (Qiagen, Valencia, CA), and genotypes were
ascertained by a mass spectrometry-based genotyping method as previously described [44]
(Sequenom, San Diego, CA). SNPs were designated by nucleotide position relative to the
translational start site on the mRNA or genomic DNA sequence, and a plus (+) or minus (−)
sign indicates a non-translated nucleotide upstream or downstream from the first translated
base pair, respectively.
Statistical Analysis
Testing for Hardy-Weinberg equilibrium and pairwise linkage disequilibrium (LD)
calculations were performed with the genhw and pwld packages in Stata, respectively
(version 9.1, StataCorp, College Station, TX). Haplotypes were inferred by using an
expectation-maximization algorithm within the DECIPHER program as implemented in
SAGE (Statistical Analysis for Genetic Epidemiology, v5.4.1, http://darwin.cwru.edu).
The risk of having a high viral load and the risk of having a rapid CD4+ T-cell count decline
was assessed in logistic regression models by TLR polymorphisms, using age and sex as
covariates in all cases [45]. For SNPs analyses, initial testing was performed using the
additive model, where SNPs were coded by the presence of 0, 1, or 2 copies of a given
allele. SNPs found to have significant associations were further tested under all possible
models against a neutral model that did not assume any mode of inheritance in order to
select the most likely model. For haplotype analyses, each haplotype within a gene was
coded by the presence of 0, 1, or 2 copies of the haplotypes and entered into a single model
using the most frequent haplotype as a reference. Multiple comparisons were accounted for
by classical Bonferroni correction using 16 independent tests for SNP analyses (one for each
independent SNP, i.e., those with R2<0.8) and four tests in the haplotype analyses (one for
each gene).
RESULTS
The demographic characteristics of the HIV-infected subjects are shown in Table 1. The
cohort included 201 participants, of whom 196 were males (98%), 193 reported a repeated
history of men having sex with men as their HIV-1 risk factor (96%), and the median age
was 33 (interquartile range 9). Data was available to assess peak viral load, setpoint viral
load and CD4+ T-cell depletion slopes in 149, 122 and 77 subjects, respectively (Table 1).
The demographics of subjects in the comparison groups in each arm of the study (high
versus low/moderate peak and setpoint viral load and rapid versus slow/moderate CD4+ T-
cell decline) were not different, except for age in the peak viral load comparison (P=0.03).
The characteristics of SNPs in the four TLRs (2, 3, 4, and 9) detected in the study population
are shown in Table 2. All tested SNPs except one (TLR4 −2604 A/G) were at Hardy-
Weinberg equilibrium. The primers used to genotype TLR4 −2604 A/G were used
successfully to genotype other cohorts during the same study period, suggesting that the
absence of equilibrium was not due to a technical issue, but rather to a random effect, and/or
the small sample size. One SNP was present at a frequency of less than 5%, and therefore
was not included in the analyses (TLR2 2258 G/A, rs5743708, minor allele frequency 4%).
As expected from previous observations, two SNP pairs were in strong LD (TLR4 1063 A/G
and 1363 C/T, R2=1; and TLR9 +1174 G/A and 1635A/G, R2=0.97) [20,24].
The risk of having a high viral load by TLR polymorphisms was assessed in logistic
regression models, after adjustment for age and sex (Table 3). We observed that 2 TLR4
SNPs in strong LD (1063 A/G [D299G] and 1363 C/T [T399I]) were associated with the
high peak viral load phenotype; 74%, 26% and 0% of subjects with high peak viral load had
0, 1 and 2 copies of the minor allele, respectively, versus 95%, 4% and 1% of low/moderate
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peak viral load subjects (OR=4.70, 95% confidence interval [CI] 1.65–13.36, adjusted
P=0.004 under the additive model; OR=6.65, 95% CI 2.16–20.46, adjusted P<0.001, under
the dominant model, Tables 3 and 4). This difference was still significant after correction for
multiple testing (P=0.002, dominant model). We also observed that two TLR3 SNP (−8921
A/T and 1234 C/T) tended to be associated with peak viral load, but these associations were
not significant after correction for multiple testing (P=0.8 and P=1.0, respectively).
The SNPs associated with high peak viral load were not associated with high viral load
setpoint or rapid HIV-1 disease progression as measured by CD4 slope. However, we
observed that two SNPs in TLR9 were associated with these endpoints (Tables 3 and 4). A
TLR9 SNP (1635 A/G) was protective against high viral load setpoint (OR=0.29, 95% CI
0.13–0.65, P=0.003, dominant model) and rapid progression (OR=0.45, 95% CI 0.24–0.97,
P=0.04, additive model); this difference remained significant after correction for multiple
testing for the viral load setpoint (P=0.04), but not the disease progression phenotype
(P=0.4). Another TLR9 SNP (−1237 T/C) tended to be associated with high viral load
setpoint (OR=2.12, 95% CI 0.99–4.54, P=0.05) and rapid progression (OR=3.21, 95% CI
1.16–8.90, P=0.03), but neither of these associations was significant after correction for
multiple testing (P=0.8 and P=0.4, respectively). We also observed that a TLR2 SNP
(−16934 T/A) was associated with protection against rapid progression (OR= 0.43, 9%% CI
0.20–0.92, P=0.03, under the additive model), but again, the association was not significant
after adjustment for multiple testing (P=0.5).
In the analyses by haplotype, we observed that TLR4 haplotype 7, present in TLR4 1063G
and 1363T carriers, was associated with an increased risk of having a high viral load
compared to the reference haplotype (OR=5.71, 95% CI 1.34–24.45, adjusted P=0.02, Table
5), but the association was lost after correction for multiple testing (P=0.08). We also found
that TLR9 haplotype 3, present in TLR9 −1237C and 1635G carriers, was associated with an
increased risk of having a high viral load setpoint (OR=2.54, 95%CI 1.12–5.78) as well as
rapid progression measured by CD4+ T-cell decline (OR=3.56, 95% CI 1.21–10.49, adjusted
P=0.02); however, this difference was not significant after correction for multiple testing
(P=0.1 and P=0.08, respectively).
DISCUSSION
To our knowledge, this is the first report of an association between TLR4 polymorphisms
and elevated viral load in HIV infected individuals. The two SNPs associated with the high
viral load phenotype (TLR4 D299G and T399I) are in strong LD in Caucasian populations
and have been previously associated with a reduced responsiveness to lipopolysaccharide
(LPS) in humans [46]. In addition, carriers of these SNP alleles have greater susceptibility to
infections, including respiratory syncytial virus in newborns [47,48], severe malaria [48],
and invasive aspergillosis in hematopoietic cell transplant recipients, [20,49–51].
The mechanism by which D299G may influence HIV viral load is currently unknown. LPS
in the bloodstream is indicative of microbial translocation across the gut mucosa [52–54],
and levels of serum LPS and systemic immune activation are correlatively lower in HIV-1
non-progressors compared to control populations, as measured by circulating interferon-
alpha and activated CD8+ T cells [55]. Additionally, LPS activation of TLR4 stimulates
programmed death of central and effector memory CD4+ T cells [56], but a clear link of
these observations to the D299G polymorphism is still lacking. Alternatively, the possibility
exists that the effects of TLR4 on HIV-1 viral load stem not from direct interaction with the
incoming pathogen, but from an interplay between the innate responses at colonized
mucosal surfaces and the host’s ability to fight invasive infections [57,58]. Such a proposed
ability to set an individual’s “innate immunity tone” would position both TLR4 and TLR9 as
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key systemic regulators in the mucosa [57–59], and polymorphisms in these genes could
thus impact the response to a broad range of mucosal commensals and pathogens.
To our knowledge, our study is the first to focus on the association of HIV disease
progression and TLR9 polymorphisms in a sero-incident cohort. Our results showed that the
1635G allele was associated with lower viral load setpoint and slower progression. The
results are consistent with the observations reported by Soriano-Sarabia et al., who also
found that the 1635G allele is associated with slow progression in a sero-prevalent, dynamic
therapeutic cohort [33]. However, these results are not consistent with the observations
made in the Swiss HIV Cohort Study, where the 1635G allele was associated with rapid
progression. A possible explanation for this discrepancy may be that the latter cohort
included subjects enrolled before the era of HAART, and thus may have been influenced by
onset confounding or differential-length biases [60,61]. The Seattle PIC may provide a more
accurate picture of primary disease progression based on common clinical parameters, since
it is a sero-incident cohort with viral load and CD4+ T cell measurements at close intervals
during the initial stages of HIV disease prior to ART initiation.
While evidence that TLR9 may be a critical factor in HIV pathogenesis continues to
accumulate, the mechanisms by which TLR9 interferes with HIV pathogenesis remain
unknown. Although the 1635G allele does not induce an amino-acid change, it has been
associated with lower TLR9 expression [62], and lower levels of TLR9 are found in the
memory B cells of viremic compared with aviremic HIV-infected individuals [31].
Additionally, a recent study showed that sooty mangabeys have reduced levels of innate
immune activation during apathogenic SIV infection. Moreover, plasmacytoid dendritic
cells from these animals produced substantially reduced levels of interferon alpha in
response to TLR7 and TLR9 activators [32]. The TLR9 signaling pathway, in particular,
will be important to examine in a more comprehensive manner, since isolated genetic or
protein analyses are unlikely to fully describe the interactions between HIV-1 and TLR9.
Determining the causes of heterogeneity in disease outcome following HIV-1 infection is an
ongoing challenge. By using a closely-monitored sero-incident cohort in this study, we show
associations between TLR4 polymorphisms and increased peak viral loads, as well as
between TLR9 polymorphisms decreased viral load setpoint and CD4+ T-cell decline. These
findings add to the current understanding of HIV pathogenesis by providing a basis for
future studies on mechanisms of HIV-1 disease progression. However, more research is
needed to establish reliable predictive measures that can improve HIV-1 treatment
outcomes.
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